Galectin Therapeutics (GALT) Times Interest Earned (2018 - 2026)
Galectin Therapeutics' quarterly Times Interest Earned came in at -$2.05 in Q1 2026, up 54.71% year-on-year from -$1.33 in Q1 2025, and down 18.17% quarter-over-quarter from -$1.74 in Q4 2025.
Galectin Therapeutics has reported Times Interest Earned for 9 years, with the latest figure at -$2.05 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned rose 54.71% year-over-year to -$2.05; the trailing twelve-month figure through Mar 2026 stood at -$2.15 (up 67.1% YoY), and the FY2025 full-year result was -$2.74, up 64.22% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$2.05, down from -$1.74 in the prior quarter.
- The five-year high for Times Interest Earned was -$1.74 in Q4 2025, with the low at -$43.77 in Q1 2022.
- Average Times Interest Earned over 5 years is -$14.93, with a median of -$9.17 recorded in 2024.
- Peak annual rise in Times Interest Earned reached 97.44% in 2022, while the deepest fall reached 26.47% in 2022.
- Tracing GALT's Times Interest Earned over 5 years: stood at -$34.52 in 2022, then surged by 67.3% to -$11.29 in 2023, then soared by 36.17% to -$7.2 in 2024, then jumped by 75.91% to -$1.74 in 2025, then fell by 18.17% to -$2.05 in 2026.
- The last three Times Interest Earned figures came in at -$2.05 (Q1 2026), -$1.74 (Q4 2025), and -$2.31 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.88 |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -2.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.05 |
| Dec 31, 2025 | -1.74 |
| Sep 30, 2025 | -2.31 |
| Jun 30, 2025 | -2.53 |
| Mar 31, 2025 | -4.53 |
| Dec 31, 2024 | -7.20 |
| Sep 30, 2024 | -6.07 |
| Jun 30, 2024 | -8.90 |
| Mar 31, 2024 | -9.17 |
| Dec 31, 2023 | -11.29 |
| Sep 30, 2023 | -10.98 |
| Jun 30, 2023 | -13.85 |
| Mar 31, 2023 | -22.48 |
| Dec 31, 2022 | -34.52 |
| Sep 30, 2022 | -30.19 |
| Jun 30, 2022 | -42.19 |
| Mar 31, 2022 | -43.77 |
| Dec 31, 2021 | -27.30 |
| Sep 30, 2021 | -1,177.71 |
| Jun 30, 2021 | -96.39 |
| Mar 31, 2021 | -287.14 |
| Dec 31, 2020 | -356.00 |
| Sep 30, 2020 | -269.36 |
| Jun 30, 2020 | -290.57 |
| Mar 31, 2020 | -162.91 |
| Dec 31, 2019 | -235.82 |
| Sep 30, 2019 | -130.14 |
| Jun 30, 2019 | -143.81 |
| Mar 31, 2019 | -107.59 |
| Dec 31, 2018 | -37.31 |
| Sep 30, 2018 | -30.80 |
| Jun 30, 2018 | -44.22 |
| Mar 31, 2018 | -49.74 |